Literature DB >> 25649782

Treatment of thromboangiitis obliterans (Buerger's disease) with high-potency vasodilators.

David Jiménez-Gallo1, Cristina Albarrán-Planelles1, Cintia Arjona-Aguilera1, German Blanco-Sánchez2, María Eugenia Rodríguez-Mateos2, Mario Linares-Barrios1.   

Abstract

Thromboangiitis obliterans (TAO) or Buerger's disease is a vascular inflammatory thrombotic occlusive and segmental disease affecting distal small and medium-sized arteries of the limbs. Tobacco is the main trigger factor and avoiding it is the main treatment. Frequently, it is necessary to use high-potency vasodilators, such as iloprost, bosentan, sildenafil, or alprostadil, to relieve symptoms and reduce the risk of amputation. Iloprost is the only one that has been shown to be effective in randomized clinical trials. We report the third case of TAO treated with sildenafil and a new case treated with bosentan. This condition can be diagnosed and treated by a dermatologist. We would like to highlight the excellent clinical response despite the fact that patients continued to smoke. This finding may have important therapeutic implications because early treatment may prevent amputation and can be effective even during the process of giving up smoking.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  Buerger's disease; bosentan; sildenafil; thromboangiitis obliterans

Mesh:

Substances:

Year:  2015        PMID: 25649782     DOI: 10.1111/dth.12207

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  Comparison of hyperbaric oxygen versus iloprost treatment in an experimental rat central retinal artery occlusion model.

Authors:  Suleyman Karaman; Berna Ozkan; Yusufhan Yazir; Melda Yardimoglu; Mustafa Gok; Ozgur Kara; Cigdem Vural; Selenay Rencber; Salih K Emek
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-02       Impact factor: 3.117

Review 2.  Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): A case series and review of the literature.

Authors:  Javier Narváez; Carmen García-Gómez; Lorenzo Álvarez; Pilar Santo; María Aparicio; María Pascual; Mercè López de Recalde; Helena Borrell; Joan M Nolla
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.